{"id":48944,"date":"2022-09-29T01:02:18","date_gmt":"2022-09-28T23:02:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/"},"modified":"2022-09-29T01:02:18","modified_gmt":"2022-09-28T23:02:18","slug":"eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/","title":{"rendered":"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma"},"content":{"rendered":"
\n

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced the publication of a study in the New England Journal of Medicine <\/i>entitled \u201cGPRC5D-Targeted CAR T Cells for Myeloma<\/a>.\u201d The study was led by Dr. Eric Smith of the Dana-Farber Cancer Institute, Dr. Renier Brentjens of the Roswell Park Comprehensive Cancer Center, and Dr. Sham Mailankody of the Memorial Sloan Kettering Cancer Center (MSK).\n<\/p>\n

<\/a><\/p>\n

\nThe GPRC5D binder used in the study was developed by Eureka using its proprietary E-ALPHA\u00ae platform in collaboration with MSK. Eureka and MSK licensed the binder to Juno Therapeutics\/Bristol Myers Squib in 2016 for CAR use, and to Sanofi in 2021 for non-CAR use.\n<\/p>\n

\nWhile B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with multiple myeloma, relapses associated with low-to-negative expression of BCMA are common. Preclinical studies have shown the efficacy of G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted CAR T-cell therapy in multiple myeloma, including in BCMA antigen escape models (Smith EL et al. Science Trans Med 2019).\n<\/p>\n

\nIn this study, 17 patients were enrolled and received GPRC5D CAR T-cell therapy (MCARH109), including patients who had previously received BCMA therapies. At the highest dose level (450 million CAR T cells), 1 patient had grade 4 cytokine release syndrome and neurotoxicity and 2 patients had delayed cerebellar-like toxicities; there were no treatment associated deaths. The maximum tolerated dose was identified at 150 million CAR T cells. A response was reported in 71% of the patients in the entire cohort, and in 58% of those who received the lower doses of 25 million to 150 million cells. Patients that previously relapsed after BCMA-targeted CAR T cell therapy responded similarly to those that were CAR na\u00efve.\n<\/p>\n

\n\u201cThe data confirms GPRC5D as an active immunotherapeutic target in multiple myeloma,\u201d said Eric Smith, M.D., Ph.D., and co-inventor of CARs for the targeting of multiple myeloma. \u201cWe look forward to advancing this program either as a stand-alone therapy or as a combination therapy with BCMA-targeting CARs.\u201d\n<\/p>\n

\n\u201cWe are thrilled that the positive GPRC5D-directed CD28\/4-1BB CAR study results were published in such a prestigious journal,\u201d said Dr. Cheng Liu, President and Chief Executive Officer at Eureka Therapeutics. \u201cThe results reaffirm our commitment to developing the next generation of safer and more effective T-cell therapies to treat patients with cancer.\u201d\n<\/p>\n

\nABOUT EUREKA THERAPEUTICS, INC.<\/b>\n<\/p>\n

\nEureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS\u00ae cell receptor platform<\/a> and E-ALPHA\u00ae antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1<\/a> for adults and ARYA2<\/a> for pediatrics) and ECT204 (ARYA3<\/a>), in Phase I\/II US trials in patients with advanced liver cancer.\n<\/p>\n

\nEureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEureka Therapeutics, Inc.
\n
Natalie Liu
\n
Investor Relations
\n
510-318-9215
\n
IR@eurekainc.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced the publication of a study in the New England Journal of Medicine entitled \u201cGPRC5D-Targeted CAR T Cells for Myeloma.\u201d The study was led by Dr. Eric Smith of the Dana-Farber Cancer Institute, Dr. Renier Brentjens of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48944","6":"format-standard","7":"category-industry"},"yoast_head":"\nEureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced the publication of a study in the New England Journal of Medicine entitled \u201cGPRC5D-Targeted CAR T Cells for Myeloma.\u201d The study was led by Dr. Eric Smith of the Dana-Farber Cancer Institute, Dr. Renier Brentjens of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T23:02:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220928006076\/en\/774526\/21\/Eureka_logo_med.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma\",\"datePublished\":\"2022-09-28T23:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/\"},\"wordCount\":552,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928006076\\\/en\\\/774526\\\/21\\\/Eureka_logo_med.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/\",\"name\":\"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928006076\\\/en\\\/774526\\\/21\\\/Eureka_logo_med.jpg\",\"datePublished\":\"2022-09-28T23:02:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928006076\\\/en\\\/774526\\\/21\\\/Eureka_logo_med.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928006076\\\/en\\\/774526\\\/21\\\/Eureka_logo_med.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/","og_locale":"en_US","og_type":"article","og_title":"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma - Pharma Trend","og_description":"EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced the publication of a study in the New England Journal of Medicine entitled \u201cGPRC5D-Targeted CAR T Cells for Myeloma.\u201d The study was led by Dr. Eric Smith of the Dana-Farber Cancer Institute, Dr. Renier Brentjens of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-28T23:02:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220928006076\/en\/774526\/21\/Eureka_logo_med.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma","datePublished":"2022-09-28T23:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/"},"wordCount":552,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928006076\/en\/774526\/21\/Eureka_logo_med.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/","url":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/","name":"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928006076\/en\/774526\/21\/Eureka_logo_med.jpg","datePublished":"2022-09-28T23:02:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220928006076\/en\/774526\/21\/Eureka_logo_med.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220928006076\/en\/774526\/21\/Eureka_logo_med.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/eureka-therapeutics-announces-new-england-journal-of-medicine-publication-of-clinical-study-demonstrating-gprc5d-as-an-active-target-for-the-treatment-of-multiple-myeloma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48944"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48944\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}